Abstracting and indexing services form the backbone of modern scientific communication. When a journal is accepted into the Science Citation Index Expanded, it means that its published articles are systematically cataloged, metadata is extracted and standardized, and the content becomes discoverable through the Web of Science platform maintained by Clarivate. This process is far more than a bureaucratic formality. Inclusion in a major citation index determines whether researchers around the world can efficiently locate, retrieve, and cite a journal’s content. For pharmaceutical scientists, whose work often spans chemistry, pharmacology, formulation science, and clinical research, discoverability through trusted indexes is essential to ensuring that findings reach the practitioners and regulators who can act upon them.

The Science Citation Index Expanded, originally established as part of the Science Citation Index created by Eugene Garfield in the 1960s, has long served as one of the most selective and influential databases in academic publishing. Journals are admitted only after a rigorous evaluation process that examines editorial rigor, peer-review integrity, regularity of publication, international editorial diversity, and the citation behavior of the published literature. The fact that the Journal of Pharmaceutical Investigation entered SciSearch coverage in 2021 means that its articles published from that year onward are now tracked within the citation network that underpins modern bibliometrics, including the annual Journal Impact Factor calculations.

The Impact Factor itself remains the most widely recognized, and most widely debated, quantitative measure of a journal’s influence. Calculated each year by Clarivate, the metric reflects the average number of citations received in a given year by articles published in the journal during the two preceding years. An Impact Factor of 5.5 for 2022 indicates that, on average, articles published in the journal in 2020 and 2021 were cited 5.5 times in 2022 across the indexed literature. In the highly competitive Pharmacology and Pharmacy category, where hundreds of journals compete for the attention of a global research community, this average places the Journal of Pharmaceutical Investigation in the top tier of its discipline.

The quartile designation adds important context to the raw number. Ranking 48th among 278 journals in Pharmacology and Pharmacy corresponds to the Q1 band, the highest quartile of the category. Quartile rankings are derived by ordering all journals in a category by their Impact Factor and dividing the list into four equal groups. Q1 status is frequently used by research institutions, funding agencies, and university committees as a shorthand marker of journal prestige, influencing decisions about where researchers submit their work, how publications are weighted in hiring and promotion evaluations, and which journals libraries prioritize in their subscriptions. For authors weighing where to publish their pharmaceutical research, a Q1 designation with a 5.5 Impact Factor signals a venue with demonstrated reach and citation performance.

Pharmacology and pharmacy is one of the most densely populated categories in the Web of Science, reflecting the breadth of research that falls under its umbrella. The category encompasses basic pharmacological research into drug receptors and signaling pathways, medicinal chemistry and drug design, pharmacokinetics and drug metabolism, formulation and delivery technologies, clinical pharmacology, and pharmacy practice research. Journals in this space range from highly specialized outlets focused on narrow subfields to broad-spectrum publications that cover the full arc from molecule to medicine. Within this crowded landscape, achieving a position in the upper fifth of the category requires consistent publication of work that other researchers find useful enough to cite, year after year.

The Journal of Pharmaceutical Investigation has built its reputation on content that spans pharmaceutical technology, drug delivery systems, biopharmaceutics, and the clinical investigation of medicines. Its scope reflects the realities of contemporary drug development, where advances increasingly emerge at the boundaries between disciplines. Novel formulations such as lipid nanoparticles, long-acting injectables, and targeted delivery platforms demand expertise that bridges physical pharmacy, materials science, and regulatory science. Similarly, the evaluation of biosimilars, generics, and novel therapeutic modalities requires integration of analytical chemistry, pharmacokinetic modeling, and clinical trial methodology. A journal that serves as a conduit for this interdisciplinary work occupies a valuable position in the scientific ecosystem, and its citation performance suggests that the community recognizes that value.

Indexing in SciSearch also carries practical consequences for the researchers who publish in the journal. Articles included in the Science Citation Index Expanded are assigned digital object identifiers and standardized metadata that feed into institutional research information systems, national assessment exercises, and funder reporting requirements. In many countries, publication in indexed journals is a formal criterion for doctoral degree completion, grant eligibility, and academic advancement. For authors based in the Asia-Pacific region and beyond, where the Journal of Pharmaceutical Investigation has historically maintained strong connections through its publisher and editorial network, the journal’s expanded indexing profile enhances the portability and recognition of their published work across international evaluation systems.

The timing of the journal’s entry into the citation index is also noteworthy. Coverage beginning in 2021 means the journal’s recent publication record has been captured during a period of extraordinary activity in pharmaceutical research. The global pandemic accelerated investment in vaccine technology, antiviral therapeutics, and manufacturing science, while parallel advances in biologics, cell and gene therapies, and digital health technologies reshaped the drug development pipeline. Citation activity across pharmacology surged during this period, and journals positioned at the interface of pharmaceutical formulation and clinical investigation benefited from heightened attention to their subject matter. The 5.5 Impact Factor for 2022 reflects not only the journal’s editorial strategy but also the intensity of scientific exchange in its field during the measurement window.

Looking ahead, the combination of SciSearch indexing and Q1 standing positions the Journal of Pharmaceutical Investigation to attract submissions from a broader international author base and to deepen its role in shaping discourse on pharmaceutical innovation. Metrics are never a complete measure of a journal’s contribution, and the scholarly community continues to debate the appropriate weight given to Impact Factors in research assessment. Nevertheless, the journal’s current profile, indexed from 2021 with an Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, provides an objective snapshot of its standing. For a publication devoted to the investigation of medicines from laboratory bench to patient bedside, the numbers confirm what its readers and contributors have long understood: rigorous pharmaceutical science, when curated and disseminated effectively, earns its place at the center of the global research conversation.

Subject of Research: Indexing and citation metrics of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, abstracting and indexing, Clarivate, Web of Science, pharmaceutical sciences, journal metrics, drug development